BNC-210

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
BNC-210
DrugBank Accession Number
DB19048
Background

BNC-210 is under investigation in clinical trial NCT04951076 (A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-traumatic Stress Disorder (PTSD)).

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 418.497
Monoisotopic: 418.200490713
Chemical Formula
C24H26N4O3
Synonyms
  • 1,8-NAPHTHYRIDIN-4(1H)-ONE, 6-((2,3-DIHYDRO-1H-INDEN-2-YL)AMINO)-1-ETHYL-3-(4-MORPHOLINYLCARBONYL)-
  • 6-((2,3-dihydro-1h-inden-2-yl)amino)-1-ethyl-3-(4-morpholinylcarbonyl)-1,8-naphthyridin-4(1h)-one
External IDs
  • BNC 210
  • BNC-210
  • BNC210
  • IW 2143
  • IW-2143
  • IW2143

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
QP49AY37OY
CAS number
1020634-41-6
InChI Key
ZAEIHDZLLJCJFP-UHFFFAOYSA-N
InChI
InChI=1S/C24H26N4O3/c1-2-27-15-21(24(30)28-7-9-31-10-8-28)22(29)20-13-19(14-25-23(20)27)26-18-11-16-5-3-4-6-17(16)12-18/h3-6,13-15,18,26H,2,7-12H2,1H3
IUPAC Name
SMILES
CCN1C=C(C(=O)N2CCOCC2)C(=O)C2=CC(NC3CC4=CC=CC=C4C3)=CN=C12

References

General References
Not Available
Wikipedia
BNC-210

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
2CompletedTreatmentAgitation in the Elderly1somestatusstop reasonjust information to hide
2CompletedTreatmentPost Traumatic Stress Disorder (PTSD)2somestatusstop reasonjust information to hide
2CompletedTreatmentSocial Anxiety Disorder (SAD)1somestatusstop reasonjust information to hide

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at July 03, 2024 13:09 / Updated at July 04, 2024 03:36